Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 24, 2004. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a retirement fund.
Material Changes
The primary material change reported is a decrease in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan. As of August 19, 2004, the fund's holdings changed from 19,226,771 to 19,176,895 shares. This movement occurred at an average price of $39.04 per share.
Management Commentary and Risks
The filing notes that the Retirement Savings Plan is a discretionary fund where all employees or former employees are potential beneficiaries. Consequently, two directors, Dr. J.P. Garnier and Dr. T. Yamada, are potentially interested in the shares held in the fund in the same manner as other employees. No specific risks, contingencies, or unusual items regarding the company's operations are disclosed in this text.
Investor Verification Points
- Verify the impact of the share reduction on the total outstanding share count of the company.
- Confirm the specific ownership percentages of Dr. J.P. Garnier and Dr. T. Yamada within the retirement fund.
- Review the full 20-F annual report for comprehensive financial performance data not included in this 6-K.